CTOs on the Move

Kemberton

www.kemberton.net

 
Kemberton is a leading provider of technology-enabled revenue cycle management services to hospitals for complex claims. We specialize in the management and collection of workers compensation, motor vehicle accident claims, veteran administration and the resolution of insurance denials for hospitals and physician practice groups. Kemberton helps accelerate collection times and maximize reimbursements for over 300 hospital clients across 35 states, resulting in over $1.5 billion dollars of incremental cash payments for our clients.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.kemberton.net
  • 501 Corporate Centre Suite 600
    Franklin, TN USA 37067
  • Phone: 877.540.0749

Executives

Name Title Contact Details
William Sweeney
Chief Technology Officer and Chief Information Security Officer Profile

Similar Companies

Goode Consulting Intl

Goode Consulting Intl is a Pompano Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The Fertility Institutes

The Fertility Institutes is a world leading fertility center that offers a variety of fertility services including gender selection, PGD genetic screening, surrogacy, egg donors, IVF, and egg freezing.

San Diego Home Health Care

San Diego Home Health Care is a Encinitas, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medisiss

Medisiss is a Redmond, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Portola

Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.